Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

Xi-De Wang , Karen Reeves , Feng R Luo , Li-An Xu , Francis Lee , Edwin Clark and Fei Huang

Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA

author email corresponding author email

Genome Biology 2007, 8:R255doi:10.1186/gb-2007-8-11-r255


Published:	29 November 2007

Subject areas: Cancer, Drug discovery, Medicine

Additional files

Additional data file 1:

Biomarkers correlated with sensitivity or resistance to dasatinib.

Format: DOC Size: 308KB Download file

This file can be viewed with: Microsoft Word Viewer

Additional data file 2:

Common predictive markers identified in prostate and breast preclinical models.

Format: DOC Size: 40KB Download file

This file can be viewed with: Microsoft Word Viewer

Additional data file 3:

The hybridization data (in log scale) were normalized with the RMA algorithm. The IC₅₀in nM and log₂IC50 values as well as the classification of cell lines as resistant (R) or sensitive (S) are also provided at the top of the spreadsheet.

Format: XLS Size: 7.4MB Download file

This file can be viewed with: Microsoft Excel Viewer

Additional data file 4:

These data were used for identification of genes whose expression was modulated by dasatinib. The hybridization data (in log scale) were normalized with the RMA algorithm. The treatment and the classification of cell lines as resistant (R) or sensitive (S) are also provided at the top of the spreadsheet.

Format: XLS Size: 7.4MB Download file

This file can be viewed with: Microsoft Excel Viewer